Understand the source comparison
Best PE-22-28 Dosage for Antidepressant Effects: Protocol Comparison
| Dosage Protocol | Administration Route | Frequency | Observed BDNF Elevation | Behavioural Efficacy (FST Immobility Reduction) | Recommended Use Case | Professional Assessment ||—|—|—|—|—|—|| 0.1 mg/kg | Subcutaneous | Daily × 14 days | 25% vs baseline | Min
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Dosage Protocol | Administration Route | Frequency | Observed BDNF Elevation | Behavioural Efficacy (FST Immobility Reduction) | Recommended Use Case | Professional Assessment ||—|—|—|—|—|—|| 0.1 mg/kg | Subcutaneous | Daily × 14 days | 25% vs baseline | Minimal (10–15% reduction) | Pilot dose-finding studies only | Subtherapeutic. Insufficient TREK-1 occupancy for consistent antidepressant effects || 0.3 mg/kg | Subcutaneous | Daily × 14 days | 50% vs baseline | Moderate (30–40% reduction) | Initial efficacy screening | Threshold dose. Reliable but not maximal; suitable for initial validation || 0.5 mg/kg | Subcutaneous | Daily × 21 days | 80–90% vs baseline | Robust (50–60% reduction) | Standard preclinical protocol | Gold standard. Produces consistent, replicable antidepressant-like phenotype across studies || 1.0 mg/kg | Subcutaneous | Daily × 21 days | 85–95% vs baseline | Robust (55–65% reduction) | High-dose validation studies | Near-maximal efficacy; marginal benefit over 0.5